{
    "organizations": [],
    "uuid": "8d0dbd5f25747909cc28ea9038215df6d5367f82",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-astrazeneca-says-ema-accepts-submi/brief-astrazeneca-says-ema-accepts-submission-for-forxiga-in-adults-with-type-1-diabetes-idUSFWN1QN03N",
    "ord_in_thread": 0,
    "title": "BRIEF-Astrazeneca Says EMA Accepts Submission For Forxiga In Adults With Type-1 Diabetes​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - Astrazeneca Plc:\n* ‍EUROPEAN MEDICINES AGENCY ACCEPTS REGULATORY SUBMISSION FOR FORXIGA IN ADULTS WITH TYPE-1 DIABETES​\n* ‍SUBMISSION ACCEPTANCE IS BASED ON PHASE III DATA FROM DEPICT CLINICAL PROGRAMME FOR FORXIGA IN T1D​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-05T15:22:00.000+02:00",
    "crawled": "2018-03-06T22:09:36.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "astrazeneca",
        "plc",
        "medicine",
        "agency",
        "accepts",
        "regulatory",
        "submission",
        "forxiga",
        "adult",
        "acceptance",
        "based",
        "phase",
        "iii",
        "data",
        "depict",
        "clinical",
        "programme",
        "forxiga",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}